Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2026

29 May - 2 Jun 2026

McCormick Place, Chicago, United States of America

ASCO 2026: Sacituzumab govitecan with pembrolizumab extends PFS for some metastatic triple-negative breast cancer patients

ASCO 2026: Sacituzumab govitecan with pembrolizumab extends PFS for some metastatic triple-negative breast cancer...

ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years

ASCO 2026: Cancer vaccine sustains 49 percent melanoma reduction after 5 years

ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible hepatocellular carcinoma are superior

ASCO 2026: EMERALD-3 study shows that new combination treatment strategies for embolization-eligible...

ASCO 2026: Mobile app for symptom monitoring could help people with advanced cancer maintain their quality of life

ASCO 2026: Mobile app for symptom monitoring could help people with advanced cancer maintain their quality of life

ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and reduce side effects for advanced head and neck cancer

ASCO 2026: More accessible oral chemotherapy and ultra-low-dose immunotherapy combo may improve survival and...

ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer

ASCO 2026: Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer

ASCO 2026: Potential new targeted treatment option for people with localised high-risk prostate cancer

ASCO 2026: Potential new targeted treatment option for people with localised high-risk prostate cancer

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC

ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage...

ASCO 2026: Daraxonrasib doubles median overall survival in metastatic pancreatic cancer

ASCO 2026: Daraxonrasib doubles median overall survival in metastatic pancreatic cancer

ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses

ASCO 2026: Galleri early detection test may shift timing of cancer detection, reducing stage IV diagnoses

ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma

ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

ASCO 2026: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer

ASCO 2026: Addition of immunotherapy continues to show survival benefit in prolonged follow-up in primary advanced stage or recurrent endometrial cancer

ASCO 2026: Addition of immunotherapy continues to show survival benefit in prolonged follow-up in primary advanced...

ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell lymphomas

ASCO 2026: Combining targeted immunotherapies with standard R-CHOP delays progression of aggressive B-cell...

ASCO 2026: Implanted tile-based radiation outperforms stereotactic radiotherapy for treatment of brain metastases

ASCO 2026: Implanted tile-based radiation outperforms stereotactic radiotherapy for treatment of brain metastases

ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node dissection

ASCO 2026: Some breast cancer patients with sentinel lymph node spread can safely skip axillary lymph node...

ASCO 2026: Personalised vaccine boosts immune activity against brain cancer

ASCO 2026: Personalised vaccine boosts immune activity against brain cancer

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST

ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers

ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers

ASCO 2026: Genetic clues may reveal which rare solitary fibrous tumours are more aggressive, likely to spread

ASCO 2026: Genetic clues may reveal which rare solitary fibrous tumours are more aggressive, likely to spread

ASCO 2026: New AI tool may help personalise multiple myeloma treatment

ASCO 2026: New AI tool may help personalise multiple myeloma treatment

ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours

ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours

ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer

ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate...

ASCO 2026: Weight loss programme improves physical function, quality of life for patients with breast cancer

ASCO 2026: Weight loss programme improves physical function, quality of life for patients with breast cancer

ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer

ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer

ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue

ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue

More from ecancer